Pyoderma gangrenosum
Pyoderma gangrenosum este o boală inflamatorie a pielii, rară, în care pustulele sau nodulii dureroși devin ulcere care cresc progresiv. Pyoderma gangrenosum nu este infecțios. Tratamentele pot include corticosteroizi, ciclosporină sau diverși anticorpi monoclonali. Deși poate afecta oamenii de orice vârstă, afectează mai ales persoanele de 40 și 50 de ani.
☆ În rezultatele Stiftung Warentest din Germania din 2022, satisfacția consumatorilor față de ModelDerm a fost doar puțin mai mică decât în cazul consultațiilor plătite de telemedicină.
Pe piciorul unei persoane cu colită ulceroasă.
References
Pyoderma gangrenosum este o afecțiune rară a pielii care provoacă ulcere dureroase cu margini roșii sau violete. Este clasificată ca o boală inflamatorie și face parte dintr-un grup numit dermatoze neutrofile. Cauza pyoderma gangrenosum este complexă, implicând probleme atât cu imunitatea înnăscută, cât și cu cea adaptativă la persoanele predispuse genetic. Recent, cercetătorii s-au concentrat pe foliculul de păr ca un potențial punct de plecare al bolii.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum este o afecțiune rară a pielii care provoacă ulcere extrem de dureroase. Deși nu înțelegem pe deplin cauza acesteia, știm că implică o activitate crescută a anumitor celule imunitare. Tratarea bolii nu este încă ușoară. Avem diverse medicamente care suprimă sistemul imunitar sau îi modifică activitatea. Alături de acestea, ne concentrăm și pe tratarea rănilor și gestionarea durerii. Corticosteroizii și ciclosporina sunt adesea prima alegere pentru tratament, dar în ultimul timp, au existat mai multe cercetări privind utilizarea terapiilor biologice, cum ar fi inhibitorii de TNF-α. Aceste substanțe biologice sunt din ce în ce mai preferate, în special la pacienții cu alte afecțiuni inflamatorii și sunt utilizate mai devreme în procesul bolii.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
